The Nature Podcast ’s highlights of 2022
In this episode:00:53 How virtual meetings can limit creative ideasIn April, we heard how a team investigated whether switching from face-to-face to virtual meetings came at a cost to creativity. They showed that people meeting virtually produced fewer creative ideas than those working face-to-face, and suggest that when it comes to idea generation maybe it’s time to turn the camera off.Nature Podcast: 27 April 2022Research article: Brucks & LevavVideo: Why video calls are bad for brainstorming08:29 How the Black Death got its startThe Black Death is estimated to have caused the deaths of up to 60% of the population ...
Source: Nature Podcast - December 28, 2022 Category: Science Authors: Springer Nature Limited Source Type: podcasts
Coronapod: the open-science plan to unseat big Pharma and tackle vaccine inequity
Inequity has been a central feature of the COVID19 pandemic. From health outcomes to access to vaccines, COVID has pushed long-standing disparities out of the shadows and into the public eye and many of these problems are global. In this episode of Coronapod we dig into a radical new collaboration of 15 countries - led by the UN, and modelled on open-science. The project, called the mRNA vaccine technology transfer hub, aims to create independent vaccine hubs that could supply the global south, and take on the giants of the pharmaceutical industry in the process. But the road ahead is long - the challenges are co...
Source: Nature Podcast - July 29, 2022 Category: Science Authors: Springer Nature Limited Source Type: podcasts
TWiV 895: COVID-19 clinical update #112 with Dr. Daniel Griffin
In COVID-19 clinical update #112, Dr. Griffin reviews seroprevalence of infection-induced antibodies, Moderna filing for vaccine authorization in young children, public health impact of vaccines in US, FDA approval of first treatment for young children, phase 2 data for Sabizabulin, and post infection inflammation. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Seroprevalence of Infection-Induced Antibodies (CDC) Authorization for Vaccine in Young Children Filed (Moderna) Public Health Impact of Vaccines in US (BMJ) FDA authorizes first approved t...
Source: This Week in Virology - MP3 Edition - April 30, 2022 Category: Virology Authors: Vincent Racaniello Source Type: podcasts
Drug Pricing Theme Issue: Is Pharma Earning Too Much?, R & D Costs Required to Bring a New Drug to Market, Probiotic Safety, and more
Editor's Summary by Gregory Curfman, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the March 3, 2020 issue (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - March 3, 2020 Category: General Medicine Authors: JAMA Network Source Type: podcasts
Talk Evidence - smoking, gloves and transparency
This month we have some more feedback from our listeners (2.20)
Carl says it's time to start smoking cessation (or stop the reduction in funding for smoking reduction) (11.40) and marvels at how pretty Richard Doll's seminal smoking paper is.
It's gloves off for infection control (22.20)
Andrew George, a non-executive director of the Health Research Authori ty joins us to talk about their consultation on research transparency, and explains how you can get involved (27.04)
And we talk about a new tool for rating the transparency of pharma companies (37.40)
Reading list:
Impact of the WHO Framework Convention on Toba...
Source: The BMJ Podcast - July 10, 2019 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts
Talk Evidence - smoking, gloves and transparency
This month we have some more feedback from our listeners (2.20)
Carl says it's time to start smoking cessation (or stop the reduction in funding for smoking reduction) (11.40) and marvels at how pretty Richard Doll's seminal smoking paper is.
It's gloves off for infection control (22.20)
Andrew George, a non-executive director of the Health Research Authority joins us to talk about their consultation on research transparency, and explains how you can get involved (27.04)
And we talk about a new tool for rating the transparency of pharma companies (37.40)
Reading list:
Impact of the WHO Framework Convention on Tobacc...
Source: The BMJ Podcast - July 10, 2019 Category: General Medicine Authors: BMJ Group Source Type: podcasts
ZUMA-1: updated data and future prospects
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting held in Houston, TX, John Rossi, MS, from Kite Pharma Inc., Santa Monica, CA, presents updated data from the pivotal ZUMA-1...
Author: VJHemOnc
Added: 09/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 19, 2018 Category: Cancer & Oncology Source Type: podcasts
WHO can tackle pharma advertising
The array of options available to pharmaceutical companies, to advertise their drugs, is incredibly broad - and the amount that they spend is increasing, with some reports saying it ’s up 60% in the last five years. In most countries, there are pretty strict rules to limit the ways in which Pharma can spend their advertising dollars - but the WHO... (Source: The BMJ Podcast)
Source: The BMJ Podcast - May 3, 2018 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts
WHO can tackle pharma advertising
The array of options available to pharmaceutical companies, to advertise their drugs, is incredibly broad - and the amount that they spend is increasing, with some reports saying it’s up 60% in the last five years. In most countries, there are pretty strict rules to limit the ways in which Pharma can spend their advertising dollars - but the WHO guidelines which have informed many of those rules are now 30 years out of date.
A new analysis on bmj.com “Ethical drug marketing criteria for the 21st century“ proposes some ways in which those guidelines should be updated, we're joined two of the authors - Lisa Parker and...
Source: The BMJ Podcast - May 3, 2018 Category: General Medicine Authors: BMJ Group Source Type: podcasts
Money for editors
As journal editors, we ’re aware of the fact that we have a role to play in scientific discourse - that’s why The BMJ has been so keen to talk about the way in which scientific knowledge is constructed, through our Evidence Manifesto.
We also know that money has influence in the scientific literature - which is why w e have a zero tolerance policy for financial conflicts of interest in our educational content.
Where do journal editors fit into this?
The first step into investigating that is to find out if journal editors receive payments from pharma and device companies - and new research, published on bmj.co m doe...
Source: The BMJ Podcast - October 27, 2017 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts
Money for editors
As journal editors, we’re aware of the fact that we have a role to play in scientific discourse - that’s why The BMJ has been so keen to talk about the way in which scientific knowledge is constructed, through our Evidence Manifesto.
We also know that money has influence in the scientific literature - which is why we have a zero tolerance policy for financial conflicts of interest in our educational content.
Where do journal editors fit into this?
The first step into investigating that is to find out if journal editors receive payments from pharma and device companies - and new research, published on bmj.com does t...
Source: The BMJ Podcast - October 27, 2017 Category: General Medicine Authors: BMJ Group Source Type: podcasts
Auditing the transparency policies of pharma
If you ’ve listened to more than one of our podcasts, you’ll probably be aware of the problem of the opacity of clinical trial data - trials which are conducted by never see the light of day, or results within those trials which are never published.
Pharmaceutical companies have their own policies on what they are willing to make public, when, and... (Source: The BMJ Podcast)
Source: The BMJ Podcast - July 28, 2017 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts
Auditing the transparency policies of pharma
If you’ve listened to more than one of our podcasts, you’ll probably be aware of the problem of the opacity of clinical trial data - trials which are conducted by never see the light of day, or results within those trials which are never published.
Pharmaceutical companies have their own policies on what they are willing to make public, when, and for the first time a new audit, published on bmj.com, collates and analyses those policies.
To discuss that study I’m joined by two of the authors - Ben Goldacre, senior clinical research fellow at, and Carl Heneghan, director of, Oxford's Centre for Evidence Based Medicin...
Source: The BMJ Podcast - July 28, 2017 Category: General Medicine Authors: BMJ Group Source Type: podcasts
